cyrilzakka/clinical-trials huggingface dataset:
Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study

Observational two phase, retrospective and prospective registry study to assess the prevalence of and characterize outcomes of autonomic dysfunction (AD) in patients who undergo bariatric surgery (BS) and to better define the underlying pathophysiology of AD following BS.

Previous studies have investigated the incidence of OI (orthostatic intolerance) with BS. One recent meta-analysis only found a 5-year cumulative incidence of 4.2%, challenging reports of increased incidence. However, this same study recognized the limited and low-quality evidence investigating this phenomenon. Other meta-analyses found only four studies each that matched their search criteria, highlighting the lack of evidence. Thus, this study is designed to investigate the prevalence and better understand AD/OI after BS.

Eligibility Criteria:
Inclusion Criteria:

* Between the age of 18 - 85 years
* Can provide consent
* Negative urine B-hCG
* Continued follow-up with the bariatric surgery team.
* BS includes one of the following: gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch.
* Phase I: Underwent BS within the last 3 years
* Phase II: Will undergo BS within the next 3 months or underwent BS in the last 30 days

Exclusion Criteria:

* Unable to provide consent
* Pregnant or breastfeeding
* BMI \< 35
* Revision surgery of one of the following BS from above
* Prior history of autonomic dysfunction prior to BS
* Developed AD 72 months post-procedure
* No evidence of AD/OI
Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning.

This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments.

We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).

If you are eligible and choose to participate, we'll ask you to come in for 2 separate testing visits and 8 weeks of treatment in between.

In both the pre-treatment and post-treatment testing visit, you would complete game-like tasks on the computer, undergo a non-invasive MRI brain scan, and answer some questions about your emotional health. The entire visit takes place during 1-2 days at Stanford and lasts about 4-5 hours. We'll also ask you to complete a follow-up 12 weeks later, from home, during which we'll again ask you some questions on your emotional health.

The 8-week treatment phase will consist of your choice of either TMS (transcranial magnetic stimulation) or Pramipexole (a medication for depression). You will meet with study coordinators and MDs each week (Pramipexole) or each day (TMS) to receive treatment. You will also be asked to complete weekly online surveys to monitor your mood during the 2-month course of treatment.

To inquire more about participation, you can either sign up online or contact us.

Sign up online: http://med.stanford.edu/williamslab/research/current/rad.html Contact us: Call or text (650) 600-1609 or email rad-at-study@stanford.edu

Eligibility Criteria:
Inclusion Criteria:

* Recent experiences of anxiety and/or depression
* Ages 18-65

Exclusion Criteria:

* Specific psychiatric medications (case-by-case basis)
* A diagnosis of Bipolar 1 Disorder, Schizophrenia, or Obsessive Compulsive Disorder
* Any of the following medical conditions: Parkinson's disease; liver or kidney disease; history of epilepsy or seizures; history of cardiovascular disorders (specifically orthostatic hypotension)
Epidemiology of Acromegaly in Denmark 1991-2010

Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark.

Background: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. The annual incidence is estimated to be 3-5/million with a prevalence of 100 - 150/million. The incidence rate is however uncertain since no nationwide surveys exist. If left untreated or poorly controlled the condition is associated with progressive morbidity and an excess mortality. The primary treatment is surgery, which however only provides a cure rate of ≈ 50 -60% due to the size of the tumour. The second line treatment today is medical treatment with slow release formulations of somatostatin analogs (SA) and, more recently, a specific GH antagonist.

Accurate data on incidence rates and outcome of treatment are of obvious importance in order to provide optimal and evidence-based treatment for the disease. This is particularly relevant in light of the availability of new and effective treatment modalities such as the GH antagonist, the proper place of which in the treatment algorithm still remains controversial.

Denmark holds a unique position in terms of epidemiological studies due to the existence of well organized databases which include all its inhabitants. A recognised problem with epidemiological surveys from specialised centres is whether the figures are representative for the general population. A nationwide Danish study will profit from the fact that every Danish citizen holds a unique ID number that makes it easy to retrieve and combine pertinent data regarding health, disease and death from different registries. The investigators have previously used this for a landmark survey of another rare endocrine disease, i.e. Cushing's syndrome. This publication has been cited more than 100 times.

Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark.

Eligibility Criteria:
Inclusion Criteria:

* diagnosed with acromegaly in years 1991-2010
Optimization of PK/PD Target Attainment for Ceftriaxone in Critically Ill Patients With Community-acquired Pneumonia.

WP2.1. PK/PD target attainment Plasma exposure ELF exposure WP2.2. Predictive dosing algorithm WP2.3. ECMO subset

First, the investigators will document exposure to ceftriaxone in plasma and epithelial lining fluid.

Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed.

Finally in a small subset of ECMO patients PK exposure will be explored.

Eligibility Criteria:
Inclusion Criteria:

* Pneumonia
* Admitted to an ICU ward
* Treated with ceftriaxone

Exclusion Criteria:

* Pregnancy
* DNR code 2-3
* Renal replacement therapy
Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

Breast surgeries are one of the most common forms of surgery conducted in hospitals, and even relatively minor interventions can be associated with significant postoperative pain. The most common surgical procedure for breast cancer is modified radical mastectomy, which means removing a generous amount of skin and the entire breast with axillary evacuation. According to the literature, up to 50% of breast surgery patients experience severe acute postoperative pain, with 10-40% breast cancer patients experiencing pain a year or more after surgery.

Poorly controlled postoperative pain has negative physiological and psychological consequences. Furthermore, effective acute pain control preserves immune function both by suppressing surgical stress response and decreasing the need for general anesthetics and opioids in the perioperative period.

The ultrasound-guided modified, pectoral nerve block is a frequently used, easy, and reliable technique to provide complete analgesia during and after breast surgery. A major limitation to its use for postoperative analgesia is that the analgesic effect lasts only a few hours, after which moderate to severe pain at the surgical site may result in the need for alternative analgesic therapy. Several adjuvants have been used to prolong the analgesic duration of peripheral nerve block, including perineural/interfascial or intravenous dexamethasone.

Our aim is to explore the efficacy of 8 mg dexamethasone added to US-guided modified pectoral nerve block on postoperative pain in patients undergoing major breast surgery.

Eligibility Criteria:
Inclusion Criteria:

* female gender
* a American Society of Anesthesiologists (ASA) score of 1 or 2
* weight: body mass index (BMI) 18 - 35 kg/m2
* informed consent
* elective, unilaterale breast surgery

Exclusion Criteria:

* bleeding disorders
* any known allergy to the medication
* diabetes mellitus
* any disease that leads to alterations in the corticosteroid physiology
* drug-dependency
* BMI \<18 or \> 35
* systemic infections
* psychiatric diseases, that are associated with an alteration in the perception of pain
* tumor spread at the site of injection
* inflammation at the site of injection
* pregnancy
Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabetes

This pilot 12-week randomized open-label study compares metformin and berberine in newly diagnosed type 2 diabetes patients stratified by the TCF7L2 (rs7903146) genotype (TT vs. CC). The primary goal is to assess changes in HbA1c between metformin and berberine treated groups within each genotype. Secondary outcomes include fasting and postprandial glucose, insulin levels, HOMA-IR, body weight/BMI, lipid profile and adverse events.

The central hypothesis is that berberine, through its additional effect on TCF7L2-linked pathways, will provide superior glycemic control in high-risk TT carriers compared to metformin, whereas both treatments will yield comparable results in CC carriers. By enrolling only TT and CC genotypes, this study aims to estimate effect sizes and feasibility, guiding a future, larger-scale trial on genotype-tailored diabetes therapies.


Eligibility Criteria:
Inclusion Criteria:

* Adults aged 30-65 years;
* Newly diagnosed T2DM ≤1 year;
* Baseline HbA1c: 7.0-9.0% (53-75 mmol/mol);
* No prior use of antihyperglycemic agents or ≤4 weeks of usage;
* Willing to sign informed consent and undergo TCF7L2 genotyping;
* TT or CC genotype (rs7903146)

Exclusion Criteria:

* Severe comorbidities (hepatic, renal, cardiac dysfunction);
* Pregnancy or lactation;
* Known allergy or intolerance to metformin or berberine;
* Participation in another clinical trial within the last 3 months;
* TC genotype (excluded).
Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section

Pruritus is the commonest side effect of intrathecal morphine especially in parturient, but the exact mechanism of pruritus is not clear. Many mechanisms have been suggested. Among these mechanisms is the activation of the 5-HT3 receptors by the intrathecally injected morphine.

Forty parturients underwent elective cesarean section under spinal anesthesia were divided into two groups of 20 each in this prospective randomized study. Group I received 100 µg of intrathecal morphine (ITM) mixed with 12 mg of 0.5% heavy bupivacaine (M100) while group II received 200 µg of ITM mixed with 12 mg of 0.5% heavy bupivacaine (M200). Two blood samples were taken from each patient for serotonin estimation, preoperatively and 4 hrs later. Postoperatively all patients were assessed for pruritus (incidence \& severity), visual analog scale (VAS), first request of analgesia, and total analgesic dose required within 24 hrs.

Eligibility Criteria:
Inclusion Criteria:

* ASA I - II term pregnant patients scheduled for elective cesarean section

Exclusion Criteria:

* patients with a known allergy to the study drugs
* significant cardiac, respiratory, renal, neurological, or hepatic disease; -coagulation disorders
* BMI \> 30 kg/m2
* any itchy skin diseases.
Patient Anxiety During Radiological Examination

This clinical trial design evaluates whether hand massage reduces anxiety levels in cancer patients as they undergo radiological examination to evaluate tumor response. Anxiety levels will be investigated before massage, after massage, and following the completion of the radiological exam. The Visual Analog Scale (VAS), a validated anxiety assessment tool, will be used to measure anxiety.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Age ≥ 18 years
* Scheduled to undergo radiologic imaging evaluation of a tumor

Exclusion Criteria:

* Known hand injury within 30 days prior to study participation
* Known pregnancy
* Mental disability as determined by the treating physician
* Actively receiving radiation therapy
* Actively receiving chemotherapy
Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

The objective of this study is to obtain blood samples from patients who are or were participants in any Alcon AL-3789 clinical trial. Association will be conducted to search for genetic markers in patients with glaucoma or ocular hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Patient must be currently or previously enrolled in Alcon clinical study and received AL-3789

Exclusion Criteria:

* Age related
Effects of Percussive Massage Treatment With Theragun on Post Exercise Delayed Onset Muscle Soreness

This project will be Randomized control trial conducted to check the effects of percussive massage treatment with theragun on pain and muscle length on post exercise delayed onset muscle soreness (DOMS) of calf muscles in healthy population so that we can have best treatment option for people with delayed onset muscle soreness, duration will be of 6months,purposive sampling will be done, subject following eligibility criteria from kasrat health and fitness club, will randomly allocated in two groups, baseline assessment will be done, group A will be treated with 5 minutes of percussive massage and 5 minuties of static stretching exercises, while group B will be managed with 5 minutes of static stretching exercises only. Assessment will be done via, Numeric Pain Rating Scale(NPRS), Short-Form McGill Pain Questionnaire (SF-MPQ) and goniometric measurements of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediately post intervention data will be analyzed by using SPSS version 25

Percussive therapy is a form of soft tissue manipulation the same thing that a massage therapist does during a massage, and is intended to reduce muscle soreness and increase muscle length. The aim of the current study is to determine the effects of percussive massage with theragun and static stretching exercises on muscle length and pain of calf muscles on post exercise (DOMS) delayed onset muscle soreness. It will be a randomized control trail, where initial screening will be done as per the inclusion criteria of healthy female gym users with minimum one week of joining time and developed post-exercise DOMS and ages ranged from 20 to 30 years. Participants with the history of lower leg injuries, any type of neuromuscular disorder and elite level of fitness will be excluded. All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be randomly place into experimental and control groups. Experimental group will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises, while the control group will be managed with 5 minutes of static stretching exercises only. Participants in both the groups will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.

Eligibility Criteria:
Inclusion Criteria:

Healthy Females will be included Participant's age will be between of 20-30 years Who develops post exercise DOMS after 15 minutes treadmill, 15 minutes stationary bicycle

Exclusion Criteria:

Subject with history of lower extremity injuries Any history type of muscular disorder Elite level of fitness excluded in this study
Role of Exercise in Diastolic Heart Failure

Diastolic heart failure is now being recognized as a key form of heart failure in older people. The focus of this research is to study ways to improve and maintain physical activity and functioning. This knowledge may improve the health and well-being in people with diastolic heart failure.

The purpose of this project is to better understand how endurance and fatigue relate to performing daily activities and how we might better improve endurance and reduce fatigue through an exercise program.

Eligibility Criteria:
Inclusion Criteria:

* Age 60 and over
* Evidence of diastolic dysfunction on echocardiogram
* Normal Left Ventricular Function (LVEF≥50%)
* Heart Failure-NYHA Class II/III
* Able and willing to participate in exercise program
* Able to come to Ann Arbor Michigan for testing

Exclusion Criteria:

* Regularly exercising(30 minute per day, 3 times per week)
* Orthopedic or musculoskeletal condition that limits weight bearing
* Uncontrolled atrial fibrillation
* History of heart valve replacement
* Unstable or serious medical condition (ie. on dialysis, oxygen; severe anemia, uncontrolled blood pressure or coronary artery disease)
Fox BioNet Project: LRRK2-002

The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.

Primary Objectives:

* Assess the levels of phosphorylated LRRK2 and LRRK2-phosphorylated Rabs, as measures of LRRK2 kinase activity, in PBMCs and neutrophils from LRRK2 PD, idiopathic PD, non-manifesting LRRK2 mutation carriers and healthy controls.
* Assess the levels of mtDNA damage in buffy coat from LRRK2 PD, idiopathic PD, non-manifesting LRRK2 mutation carriers and healthy controls.
* Correlate LRRK2 kinase activity to mtDNA damage in blood from LRRK2 PD, idiopathic-PD, non-manifesting LRRK2 mutation carriers and healthy controls.

Secondary Objectives:

* To assess the ability of the network to efficiently conduct a study involving biosample collection for PD research. Efficiency will be assessed using measures of the time taken to meet specific milestones within the study.
* To assess the ability of the network to collect high quality biospecimens adhering to agreed-upon, standardized protocols
* To gauge the willingness of participants to participate in subsequent Fox BioNet studies

Eligibility Criteria:
Inclusion Criteria:

LRRK2 Parkinson Disease (PD) Subjects:

* Patients must have confirmed LRRK2 mutation
* Patients must meet the MDS criteria for Parkinson's disease
* Disease duration: any
* Male or female age 30 years or older at time of PD diagnosis.

Idiopathic PD Subjects:

* Patients must meet the MDS criteria for Parkinson's disease.
* Disease duration: any
* Male or female age 30 years or older at time of PD diagnosis.

Non-manifesting LRRK2 mutation carriers:

* Patients must have confirmed LRRK2 mutation
* Male or female age 30 years or older at Screening.

Control (C) Subjects:

* Male or female age 30 years or older at Screening.

Exclusion Criteria:

LRRK2 Parkinson Disease (PD) Subjects:

* Inability to provide informed consent
* Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans.
* Treatment for cancer in the last 5 years.

Idiopathic PD Subjects:

* Inability to provide informed consent
* Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans.
* Treatment for cancer in the last 5 years.

Non-manifesting LRRK2 mutation carriers:

* Inability to provide informed consent
* Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans.
* Treatment for cancer in the last 5 years.

Control Subjects:

* Inability to provide informed consent
* Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans.
* Treatment for cancer in the last 5 years
Plate Fixation Versus Intramedullary Nailing of 3 and 4 Part Proximal Humerus Fractures

The purpose of the project is to compare the management of 3 and 4 part proximal humerus fractures (PHF) with an angular stable plate (Philos) with that of an intramedullary nail (Multiloc) in light of complications, radiological, economical, functional and clinical outcome.

Randomized controlled trial (RCT) from Akershus University Hospital in Norway. Randomization between two implants. The investigators will use deltopectoral or deltoid split as surgical access. All patients will have calcar screws and cuff sutures. When lack of bone for example after decompressing valgus compressed fractures, a bone-substitute might be used in the surgeons preference. Follow up in outpatient clinic at 6, 12, 52 and 104 weeks, but also a 5 year follow up is planned. Postoperative radiographs of both shoulders and CT of operated shoulder will be taken.

Eligibility Criteria:
Inclusion Criteria:

1. Patients \> 18 years
2. Severe displacement, defined as malposition of at least 45⁰ of angular deviation in valgus or 30⁰ in varus in true frontal projection, regardless of whether the fracture is impacted or not. Fractures with more than 50% displacement of the head against the surgical neck
3. The greater or lesser tubercles must be fractured in a 3 or 4-part fracture. The degree of displacement is not critical for inclusion.

Exclusion Criteria:

Exclusion criteria:

1. Fracture more than 3 weeks' old
2. Caput humeri just a thin shell or split
3. Ipsilateral damage that will influence the recovery and scoring systems
4. Incapability to protect osteosynthesis, i.e. use of crutches because of injury to lower extremity.
5. Pathological fracture
6. Neurovascular injury
7. Open fracture
8. Noncompliance
9. Congenital anomaly
10. Ongoing infectious process around the incision site for plate osteosynthesis
11. Systemic disease that may influence healing processes or scoring systems (RA/MS)
12. Fracture dislocation
13. Substance abuse
14. Inability to read and understand Norwegian
15. Patients not residing in our catchment area
16. Patients with too small humerus diameter to use a nail
17. Patient not able to commit and understand written consent